Recombinant human erythropoietin in children with cancer

Journal of Pediatric Hematology/Oncology

Volumn 20, Issue 3, 1998, Pages 187-189

  MacMillan, Margaret L ^a   Freedman, Melvin H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BONE MARROW CELL; CANCER SURVIVAL; CHILDHOOD CANCER; CHRONIC DISEASE; PRIORITY JOURNAL; RETICULOCYTE COUNT; VIRUS TRANSMISSION;

ANEMIA; CHILD; CLINICAL TRIALS; ERYTHROPOIETIN, RECOMBINANT; HUMANS; NEOPLASMS;

EID: 0031869650     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199805000-00001     Document Type: Article

References (27)

1. Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689-92.
2. Dainiak N, Kulkarni V, Howard D, et al. Mechanisms of abnormal erythropoiesis in malignancy. Cancer 1983;51:1101-6.
3. Beguin Y. Biology and clinical uses of erythropoietin in infants and children. Int J Pediatr Hematol Oncol 1995;2:475-490.
4. Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 1992;79:1987-94.
5. Matsumoto T, Endoh K, Kamisango K, et al. Effects of recombinant human erythropoietin on anticancer drug-induced anaemia. Br J Haematol 1990;75:463-8.
6. Goodnough LT, Monk TG, Andriole GL. Erythropoietin therapy. N Engl J Med 1997;336:933-7.
7. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer 1993;Suppl 2:S2-S8.
8. Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62.
9. De Campos E, Radford J, Steward W, et al. Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1995;13:1623-31.
10. Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994;21, Suppl 3:21-8.
11. Ludwig H, Sundal E, Pecherstorfer, M, et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1995;76:2319-29.
12. Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992;84:98-103.
13. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
14. Granolleras C, Leskopf W, Shaldon S, et al. Experience of pain after subcutaneous administration of different preparations of recombinant human erythropoietin: a randomized, double-blind crossover study. Clin Nephrol 1991;36:294-8.
15. Klaesson S, Ringdén O, Ljungman P, et al. Reduced blood transfusions requirements after allogeneic bone marrow transplantation: results of a randomised, double-blind study with high-dose erythropoietin. Bone Marrow Transplant 1994;13:397-402.
16. Spivak JL. Recombinant human erythropoietin and the anemia of cancer. Blood 1994;84:997-1004.
17. Beck MJ, Beck D. Recombinant erythropoietin in acute chemotherapy-induced anemia of children with cancer. Med Pediatr Oncol 1995;25:17-21.
18. Bolonaki I, Stiakaki E, Lydaki E, et al. Treatment with recombinant human erythropoietin in children with malignancies. Pediatr Hematol Oncol 1996;13:111-21.
19. Biggs JC, Atkinson KA, Booker V, et al. Prospective randomised double-blind trial of the in vivo use of recombinant human erythropoietin in bone marrow transplantation from HLA-identical sibling donors. Bone Marrow Transplant 1995;15:129-34.
20. Pedrazzini A. Erythropoietin and GM-CSF following autologous bone marrow transplantation. Eur J Cancer 1993;29A:S15-S17.
21. Ayash LJ., Elias A, Hunt M, et al. Recombinant human erythropoietin for the treatment of the anaemia associated with autologous bone marrow transplantation. Br J Haematol 1994;87:153-61.
22. Bequin Y, Oris R, Fillet G. Dynamics of erythropoietic recovery following bone marrow transplantation: role of marrow proliferative capacity and erythropoietin production in autologous versus allogeneic transplants. Bone Marrow Transplant 1993;11:285-92.
23. Locatelli F, Zecca M, Pedrazzoli P, et al. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants. Bone Marrow Transplant 1994;13:403-10.
24. Akingbola A, Custer JR, Bunchman TE, et al. Management of severe anemia without transfusion in a pediatric Jehovah's Witness patient. Crit Care Med 1994;22:524-8.
25. Johnson PWM, King R, Slevin ML et al. The use of erythropoietin in a Jehovah's Witness undergoing major surgery and chemotherapy. Br J Cancer 1991;63:476.
26. Schiff SJ, Weinstein SL. Use of recombinant human erythropoietin to avoid blood transfusion in a Jehovah's Witness requiring hemispherectomy. J Neurosurg 1993;79:600-2.
27. Van Kaam AH, Egeler RM. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer 1996;78:114-5.